4Jack CR, Bemstein MA, Fox NC, et al. The Alzheimer 's disease neuroim- aging initiative (ADNI) :MRI methods[ J]. Magn Reson Imaging, 2008; 27(4) :685-91.
5Ding B,Chen KM,Ling HW,et al. Correlation of iron in the hippocam- pus with MMSE in patients with Alzheimerg disease[J]. J Magn Reson Imaging, 2009;29(4) :793-8.
6Xia C,Wang G, Sun J, et al. Simultaneous determination of ginsenoside Rgl, Re, Rd, Rbl and ophiopogonin D in rat plasma by liquid chro- matography/electrospray ionization mass spectrometric method and its application to pharmacokinetic study of ' SHENMAI' injection [J]. J Chromatogr B Analyt Technool Bimed life,2008 ;862:72-8.
7Treiber KA, Lyketsos CG, Coreoran C,et al. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease:the Cache County Study[ J]. Int Psychogeriatr,2008 ;20(3 ) :538-53.
8Knopman D5, Parisi JE, l:loeve BF, et al. Vascular dementia in a popu- lation-based autopsy study. Arch Neurol, 2003 ;60 (4) : 569 - 575.
9Eberling JL. Estrogen has neuroproteetive effects and may reduce the risk of Alzheimerg disease . Expert Opin Biol Ther, 2002; 50(6): 56 -60.
10Loftis JM, Janowsky A. The N methyl-D aspartate receptor subunit NR2B: lcoalization ,functional properties regulation and clinical implications - Pharmacol Ther, 2003, 35(2): 69 -72.
